Stock Events

AIM ImmunoTech 

€0.34
0
+€0+0% Today

Statistics

Day High
0.38
Day Low
0.33
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.16
-0.11
-0.05
0
Expected EPS
-0.13
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HXB2.F. It's not an investment recommendation.

About

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.
Show more...
CEO
Mr. Thomas K. Equels
Employees
21
Country
UK
ISIN
US00901B1052
WKN
000A2PREX

Listings